Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  02:00 2022-09-27 am EDT
1900.00 JPY   +0.58%
06:25aUS Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astellas' Lexiscan
MT
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts
AQ
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Cancer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Shares Sink 3% as Weak Yen Drags Fiscal Q1 Attributable Profit Down

08/02/2022 | 12:39am EDT


© MT Newswires 2022
All news about ASTELLAS PHARMA INC.
06:25aUS Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astell..
MT
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
AQ
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
MT
09/12Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
CI
09/04Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
CI
08/18Astellas Pharma Gets US FDA Nod on New Drug Application for Menopause
MT
08/18ADRs End Lower, Geely Automobile Trades Actively
DJ
08/18U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
CI
08/10Verizon Business selected to transform Astellas Pharma's global network infrastructure
AQ
08/10Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
MT
More news
Financials
Sales 2023 1 454 B 10 042 M 10 042 M
Net income 2023 206 B 1 422 M 1 422 M
Net cash 2023 395 B 2 729 M 2 729 M
P/E ratio 2023 16,7x
Yield 2023 3,16%
Capitalization 3 471 B 23 970 M 23 970 M
EV / Sales 2023 2,12x
EV / Sales 2024 1,93x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 1 900,00 JPY
Average target price 2 596,15 JPY
Spread / Average Target 36,6%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.0.99%23 910
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989